15
ALL7
Everest Medicines1
Ewha Womans University1
La Jolla Pharmaceutical1
Shanghai Pharma Group1
SOM Biotech4
Tetraphase PharmaceuticalsYear
15
ALL4
20233
20221
20217
2020DEALS // DEV.
15
ALL7
Deals8
DevelopmentsCountry
15
ALL1
CHINA1
SOUTH KOREA1
SPAIN12
U.S.A15
ALL1
AcelRx Pharmaceuticals1
Armistice Capital1
Everest Medicines8
Inapplicable1
La Jolla Pharmaceutical1
Melinta Therapeutics1
SOM Biotech1
TTY BIOPHARM CO LTDTherapeutic Area
15
ALL15
Infections and Infectious DiseasesStudy Phase
15
ALL12
Approved FDF1
Phase I2
PreclinicalDeal Type
15
ALL2
Acquisition1
Collaboration1
Financing8
Inapplicable1
Merger2
PartnershipProduct Type
15
ALL15
Other Small MoleculeDosage Form
15
ALL12
Intravenous Injection3
UndisclosedLead Product
15
ALL15
EravacyclineTarget
15
ALL15
30S ribosomal subunitLead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China
Details : XERAVA® (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is bacteriostatic which disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TTY BIOPHARM CO LTD
Deal Size : Undisclosed
Deal Type : Partnership
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan
Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TTY BIOPHARM CO LTD
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired MDR and are pr...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and a...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2021
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.
Product Name : TP-434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : $55.0 million
Deal Type : Merger
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
Details : Through this acquisition, Melinta will enhance its commercial portfolio with XERAVATM. Once the transaction closes, Melinta will have a portfolio of five complementary marketed antibiotics: VABOMERE, ORBACTIV, BAXDELA, MINOCIN for Injection, and XERAVATM...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : $55.0 million
September 06, 2020
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Melinta Therapeutics
Deal Size : $55.0 million
Deal Type : Merger